Sample population sizes varied across the 9 studies, ranging between 9 and 45 participants
The article names immunocompromised status, a history of small intestinal bacterial overgrowth, and inflammatory bowel disease as situations requiring individualized provider assessment before starting a probiotic
The clinical evidence is clearest for two approaches: liposomal delivery (faster blood level increases, shown in the Sinha et al
2,3 Furthermore, several cardiovascular outcome trials (CVOT) suggest GLP-1 RAs confer a mortality benefit, with significant reductions in major adverse cardiovascular events, all-cause mortality, heart failure severity, and worsening kidney function
to reconcile the genetics and observational estimates additional longitudinal and experimental studies are needed
A guide to designing germline-dependent epigenetic inheritance experiments in mammals